High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Higher tumor mutational burden (TMB) has been correlated with response to checkpoint blockade immunotherapy. However, it is unclear whether TMB independently serves as a prognostic biomarker for outcomes in immunotherapy-naïve patients. Here we evaluated the relationship between TMB and overall surv...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Riviere, Paul, Goodman, Aaron M, Okamura, Ryosuke, Barkauskas, Donald A., Whitchurch, Theresa J, Lee, Suzanna, Khalid, Noor, Collier, Rachel, Mareboina, Manvita, Frampton, Garrett M., Fabrizio, David, Sharabi, Andrew B., Kato, Shumei, Kurzrock, Razelle
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7541603/
https://ncbi.nlm.nih.gov/pubmed/32747422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0161
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi